Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002
ESPERION THERAP (NASDAQ: ESPR) Delayed: 3.16 --0 (-0%)
Previous Close $3.16    52 Week High $30.41 
Open $3.16    52 Week Low $9.40 
Day High $3.17    P/E N/A 
Day Low $3.15    EPS $-21.87 
Volume 5,646,804